Pharma

Xtalks Announces its Life Science Webinar Calendar for January 2024

Retrieved on: 
Wednesday, January 3, 2024
Cloud, Drug discovery, Purification, Drug development, FDA, Medical device, Gene, Peptide library, AI, Innovation, Campaign, ChromeOS, Impact, Art, Pharma, Sponsor

TORONTO, ON, Jan. 3, 2024 /PRNewswire-PRWeb/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries. Access to all webinars is free, so be sure to register today to save your place! Participate in the discussion and stay relevant in your field!

Key Points: 
  • Upcoming free, educational webinars from Xtalks will feature topics on cell and gene therapy, clinical trials, commercialization & HEOR, drug discovery & development, human resources and career development, laboratory technology, medical device, pharmaceutical and pharma manufacturing & supply chain.
  • TORONTO, ON, Jan. 3, 2024 /PRNewswire-PRWeb/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries.
  • Access to all webinars is free, so be sure to register today to save your place!
  • Participate in the discussion and stay relevant in your field!

Switch Therapeutics Appoints Charles Allerson, Ph.D., as Chief Technology Officer

Retrieved on: 
Wednesday, January 3, 2024
Health, Hospitals, Genetics, General Health, Pharmaceutical, Biotechnology, RNA, Senior, Science, Drug discovery, Regulus Therapeutics, TANGO, Iron monosilicide, Research, Acquisition, Therapy, Novartis, Medicinal chemistry, CNS, Bangladesh Technical Education Board, Conditional, Central nervous system, Pharma, Lafayette College, Harvard University, Vaccine

Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat diseases utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the appointment of Charles Allerson, Ph.D., as Chief Technology Officer (CTO).

Key Points: 
  • Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat diseases utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the appointment of Charles Allerson, Ph.D., as Chief Technology Officer (CTO).
  • He succeeds Si-ping Han, Ph.D., co-founder of Switch Therapeutics, who will transition to an advisory role and serve on Switch’s Scientific Advisory Board.
  • “Charles joins our leadership team with extensive expertise in oligonucleotide chemistry and RNA-based therapeutics, and we are delighted to welcome him to Switch.
  • He will play a crucial role as we continue driving our novel CASi platform forward for the treatment of central nervous system (CNS) diseases,” said Dee Datta, Ph.D., co-founder and CEO of Switch Therapeutics.

Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital

Retrieved on: 
Tuesday, January 2, 2024
Hercules, VRNA, Health care, COPD, Chronic obstructive pulmonary disease, Pharming, Growth, Patient, Pharma, Creditor, Senior

LONDON and RALEIGH, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces it and its wholly-owned subsidiary, Verona Pharma, Inc. (the “Company”), have entered into a debt financing facility (“debt facility”) providing the Company with access to up to $400 million from funds managed by Oxford Finance LLC (“Oxford”) and Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”) (collectively, the “Lenders”).

Key Points: 
  • LONDON and RALEIGH, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces it and its wholly-owned subsidiary, Verona Pharma, Inc. (the “Company”), have entered into a debt financing facility (“debt facility”) providing the Company with access to up to $400 million from funds managed by Oxford Finance LLC (“Oxford”) and Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”) (collectively, the “Lenders”).
  • The debt facility replaces the existing facility of up to $150 million with an affiliate of Oxford.
  • Verona Pharma will pay only interest on the outstanding loans under the debt facility for the first 53 months with the outstanding principal of the loans under the debt facility amortized over the subsequent 7 months.
  • The $20 million drawn and fees and associated costs due to Oxford on the discharge of the existing debt facility will be paid to Oxford on closing of the debt facility.

Veteran MedTech leader and hospital group CEO joins CMR Surgical as global Chief Commercial Officer

Retrieved on: 
Monday, December 11, 2023
Marketing, CMR, Johnson & Johnson, Medtech, Medical device, Surgeon, Hospital, GMT, CMR Surgical, Smith & Nephew, Smith, Emerging market, Growth, Patient, Pharma, Nursing

CMR Surgical (“CMR” or “the Company”), the global surgical robotics business, today announces that Massimiliano Colella has joined the Company as global Chief Commercial Officer.

Key Points: 
  • CMR Surgical (“CMR” or “the Company”), the global surgical robotics business, today announces that Massimiliano Colella has joined the Company as global Chief Commercial Officer.
  • The appointment comes as CMR accelerates its already successful installations of Versius, bringing minimal access surgery to more patients around the world.
  • Massimiliano joins CMR from Evercare Group, a leading hospital group, where he served as Group Chief Executive Officer and Board member.
  • Having led a large hospital group, the momentum and need for surgical robotics is only growing, both to bring more equity of care for patients, and to look after our surgical workforce.

Veteran MedTech leader and hospital group CEO joins CMR Surgical as global Chief Commercial Officer

Retrieved on: 
Monday, December 11, 2023
Marketing, CMR, Johnson & Johnson, Medtech, Medical device, Surgeon, Hospital, GMT, CMR Surgical, Smith & Nephew, Smith, Emerging market, Growth, Patient, Pharma, Nursing

CMR Surgical (“CMR” or “the Company”), the global surgical robotics business, today announces that Massimiliano Colella has joined the Company as global Chief Commercial Officer.

Key Points: 
  • CMR Surgical (“CMR” or “the Company”), the global surgical robotics business, today announces that Massimiliano Colella has joined the Company as global Chief Commercial Officer.
  • The appointment comes as CMR accelerates its already successful installations of Versius, bringing minimal access surgery to more patients around the world.
  • Massimiliano joins CMR from Evercare Group, a leading hospital group, where he served as Group Chief Executive Officer and Board member.
  • Having led a large hospital group, the momentum and need for surgical robotics is only growing, both to bring more equity of care for patients, and to look after our surgical workforce.

CHOU2 PHARMA Takes Center Stage as Local Host of Philadelphia iHeartRadio & Q102’s Jingle Ball Backstage Lounge on December 12

Retrieved on: 
Saturday, December 9, 2023
Jelly roll, Music, Pet, IHeartRadio, Big Time Rush, Animal, Love, Social media, Usher, OneRepublic, Pharma, Comfort

PHILADELPHIA, Dec. 08, 2023 (GLOBE NEWSWIRE) -- CHOU2 PHARMA (or CHOU2), a veterinary health supplement company leveraging pure, proprietary, and unconditionally clean cannabinoid products for pets, is proud to announce its local sponsorship of the Backstage Lounge at the highly anticipated, sold-out Philadelphia Jingle Ball on Tuesday, December 12.

Key Points: 
  • PHILADELPHIA, Dec. 08, 2023 (GLOBE NEWSWIRE) -- CHOU2 PHARMA (or CHOU2), a veterinary health supplement company leveraging pure, proprietary, and unconditionally clean cannabinoid products for pets, is proud to announce its local sponsorship of the Backstage Lounge at the highly anticipated, sold-out Philadelphia Jingle Ball on Tuesday, December 12.
  • In a festive celebration of music and compassion, Chou2 Pharma is dedicated to making a lasting impact on the lives of animals in need.
  • “Chou2 Pharma invites everyone to join in the giving spirit this season, especially to the loving animals in our lives who cannot speak for themselves.
  • “Chou2 is thrilled to sponsor the backstage lounge in our founding city of Philadelphia.

Down Syndrome Clinical Trials 2023: Comprehensive Global Analysis Report, Highlighting Regional Trends, Phases, and Sponsor Types - ResearchAndMarkets.com

Retrieved on: 
Friday, December 22, 2023
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Clinical trial, Trial, News, G7, E7, Down syndrome, Pharma, Clinical, Pharmaceutical industry

The clinical trial report, provides an overview of Down Syndrome Clinical trials scenario.

Key Points: 
  • The clinical trial report, provides an overview of Down Syndrome Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Down Syndrome.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
  • Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe.

Ascendis Pharma Resubmits NDA for TransCon™ PTH to the U.S. FDA

Retrieved on: 
Wednesday, November 15, 2023
NDA, Type, PTH, Patient, FDA, United, Southern Transcon, Health, New Drug Application, Hypoparathyroidism, Parathyroid hormone, Pharma, Pharmaceutical industry

COPENHAGEN, Denmark, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has resubmitted its New Drug Application (NDA) for TransCon PTH (palopegteriparatide) for the treatment of adults with hypoparathyroidism to the U.S. Food & Drug Administration (FDA).

Key Points: 
  • COPENHAGEN, Denmark, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has resubmitted its New Drug Application (NDA) for TransCon PTH (palopegteriparatide) for the treatment of adults with hypoparathyroidism to the U.S. Food & Drug Administration (FDA).
  • The resubmission follows the Type A meeting held with the FDA in late August.
  • “With results from two randomized, double-blind, placebo-controlled clinical trials of TransCon PTH and no new safety concerns identified in follow-up reaching up to four years, we believe TransCon PTH is well-positioned to meet the needs of the hypoparathyroidism community.
  • As no concerns were expressed by the FDA about the clinical data submitted as part of our original NDA, we look forward to working with the agency during its review of our updated manufacturing control strategy for TransCon PTH in the United States.”

NMD Pharma Raises €75 Million (~$80 million) in a Series B Financing

Retrieved on: 
Wednesday, November 15, 2023
Spinal muscular atrophy, Acetylcholine receptor, Investment, Patient, Myasthenia gravis, Novo Holdings A/S, Therapy, Charcot–Marie–Tooth disease, MuSK protein, NMD, Growth, Pharma, Pharmaceutical industry, Fine chemical

The financing was led by current investor Jeito Capital and includes investments from other current NMD Pharma investors: Novo Holdings, Lundbeckfonden BioCapital, INKEF Capital, and the Roche Venture Fund.

Key Points: 
  • The financing was led by current investor Jeito Capital and includes investments from other current NMD Pharma investors: Novo Holdings, Lundbeckfonden BioCapital, INKEF Capital, and the Roche Venture Fund.
  • NMD Pharma is developing first-in-class small molecule inhibitors of the skeletal muscle specific chloride ion channel (ClC-1) to enhance neuromuscular transmission with the potential to restore muscle function in a range of rare neuromuscular diseases.
  • Proceeds from the financing will be used to complete three Phase 2 studies with NMD670, the Company’s lead ClC-1 inhibitor.
  • Furthermore, NMD Pharma will continue to expand its pipeline of ClC-1 inhibitor molecules and pursue undisclosed targets for the treatment of other neuromuscular diseases.

Global CDMO Agno Pharma Completes Acquisition of Particle Sciences Inc.

Retrieved on: 
Monday, December 18, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Acquisition, Pharma, Bethlehem

Agno Pharma (“Agno”), a US-based, global pharmaceutical contract development and manufacturing organization, announced today that it will acquire the Lubrizol Particle Sciences Inc. business (“Particle Sciences”).

Key Points: 
  • Agno Pharma (“Agno”), a US-based, global pharmaceutical contract development and manufacturing organization, announced today that it will acquire the Lubrizol Particle Sciences Inc. business (“Particle Sciences”).
  • The acquisition includes the drug product formulation technology behind the Particle Sciences Inc. business as well as the Bethlehem, PA, development and manufacturing site with approximately 65 employees.
  • Founded in 1991, Particle Sciences specializes in pre-clinical and clinical stage drug product formulation and offers a comprehensive suite of supporting services, including analytic, bioanalytic, physical characterization, and manufacturing.
  • The acquisition of Particle Sciences will provide Agno with expanded capability and capacity to extend its drug product formulation and clinical manufacturing services to its customers globally.